Teva Pharmaceutical Industries Limited [NYSE: TEVA] plunged by -$0.36 during the normal trading session on Tuesday and reaching a high of $10.24 during the day while it closed the day at $9.83. The company report on October 4, 2021 that ‘Medicine Miles’ Becoming a Concern for European Patients.
Research shows the origin of medicines becomes more important.
The pandemic has triggered a greater interest among patients about Europe’s role in medicine manufacturing.
Teva Pharmaceutical Industries Limited stock has also gained 1.03% of its value over the past 7 days. However, TEVA stock has inclined by 9.96% in the 3 months of the year. Over the past six months meanwhile, it has lost -9.65% and gained 1.87% year-on date.
The market cap for TEVA stock reached $10.78 billion, with 1.10 billion shares outstanding and 1.09 billion shares in the current float. Compared to the average trading volume of 8.61M shares, TEVA reached a trading volume of 6771990 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Teva Pharmaceutical Industries Limited [TEVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $11.47 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Teva Pharmaceutical Industries Limited shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 04, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Sector Perform. The new note on the price target was released on April 07, 2021, representing the official price target for Teva Pharmaceutical Industries Limited stock. On August 06, 2020, analysts increased their price target for TEVA shares from 10 to 13.
The Average True Range (ATR) for Teva Pharmaceutical Industries Limited is set at 0.30, with the Price to Sales ratio for TEVA stock in the period of the last 12 months amounting to 0.66. The Price to Book ratio for the last quarter was 1.05, with the Price to Cash per share for the same quarter was set at 2.22.
TEVA stock trade performance evaluation
Teva Pharmaceutical Industries Limited [TEVA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.03. With this latest performance, TEVA shares gained by 5.81% in over the last four-week period, additionally sinking by -9.65% over the last 6 months – not to mention a rise of 4.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TEVA stock in for the last two-week period is set at 56.18, with the RSI for the last a single of trading hit 55.55, and the three-weeks RSI is set at 54.97 for Teva Pharmaceutical Industries Limited [TEVA]. The present Moving Average for the last 50 days of trading for this stock 9.51, while it was recorded at 10.03 for the last single week of trading, and 10.42 for the last 200 days.
Teva Pharmaceutical Industries Limited [TEVA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Teva Pharmaceutical Industries Limited [TEVA] shares currently have an operating margin of +18.36 and a Gross Margin at +46.38. Teva Pharmaceutical Industries Limited’s Net Margin is presently recorded at -23.95.
Return on Total Capital for TEVA is now 7.87, given the latest momentum, and Return on Invested Capital for the company is -11.37. Return on Equity for this stock declined to -34.11, with Return on Assets sitting at -7.60. When it comes to the capital structure of this company, Teva Pharmaceutical Industries Limited [TEVA] has a Total Debt to Total Equity ratio set at 263.30. Additionally, TEVA Total Debt to Total Capital is recorded at 72.47, with Total Debt to Total Assets ending up at 52.13. Long-Term Debt to Equity for the company is recorded at 231.50, with the Long-Term Debt to Total Capital now at 63.72.
Reflecting on the efficiency of the workforce at the company, Teva Pharmaceutical Industries Limited [TEVA] managed to generate an average of -$345,488 per employee. Receivables Turnover for the company is 3.34 with a Total Asset Turnover recorded at a value of 0.32.Teva Pharmaceutical Industries Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.
Earnings per share (EPS) analysis for Teva Pharmaceutical Industries Limited [TEVA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva Pharmaceutical Industries Limited go to 4.80%.
Teva Pharmaceutical Industries Limited [TEVA]: Insider Ownership positions
There are presently around $5,516 million, or 51.10% of TEVA stock, in the hands of institutional investors. The top three institutional holders of TEVA stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 122,652,574, which is approximately -4.694% of the company’s market cap and around 1.05% of the total institutional ownership; CAPITAL WORLD INVESTORS, holding 49,336,350 shares of the stock with an approximate value of $484.98 million in TEVA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $420.62 million in TEVA stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Teva Pharmaceutical Industries Limited stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 168 institutional holders increased their position in Teva Pharmaceutical Industries Limited [NYSE:TEVA] by around 31,584,929 shares. Additionally, 185 investors decreased positions by around 41,932,200 shares, while 130 investors held positions by with 487,620,716 shares. The mentioned changes placed institutional holdings at 561,137,845 shares, according to the latest SEC report filing. TEVA stock had 42 new institutional investments in for a total of 3,016,075 shares, while 45 institutional investors sold positions of 5,414,751 shares during the same period.